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Summary Recent studies support the potential application of the wt-p53 gene in cancer therapy. Expression of exogenous wt-p53
suppresses a variety of leukaemia phenotypes by acting on cell survival, proliferation and/or differentiation. As for tumour gene therapy, the
final fate of the neoplastic cells is one of the most relevant points. We examined the effects of exogenous wt-p53gene expression in several
leukaemia cell lines to identify p53-responsive leukaemia. The temperature-sensitive p53vallw mutant or the human wt-p53 cDNA was
transduced in leukaemia cell lines representative of different acute leukaemia FAB subtypes, including Ml (KG1), M2 (HL-60), M3 (NB4), M5
(U937) and M6 (HEL 92.1.7), as well as blast crisis of chronic myelogenous leukaemia (BC-CML: K562, BV173) showing diverse
differentiation features. By morphological, molecular and biochemical analyses, we have shown that exogenous wt-p53 gene expression
induces apoptosis only in cells corresponding to Ml, M2 and M3 of the FAB classification and in BC-CML showing morphological and
cytochemical features of undifferentiated blast cells. In contrast, it promotes differentiation in the others. Interestingly, cell responsiveness was
independent of the vector used and the status of the endogenous p53gene.
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Gene therapy strategies to induce apoptosis in tumour cells are
regarded as powerful tools for the management of several cancers
(Ozturk et al, 1992; Gotz and Montenarh 1995). Therefore, the
identification of leukaemia cells susceptible to wt-p53-induced
apoptosis should be useful for therapeutic purposes. In spite ofthe
evidence that cellular context determines the final outcome of the
cells after wt-p53 forced expression (Canman et al, 1995; Soddu et
al, 1996), it is still unclearhow toclassify the cellularenvironments
as a function of the response to wt-p53 action. In this respect, we
asked whether the stage of differentiation might be a good para-
meter to classify the final outcome ofwt-p53-transduced leukaemia
cells. To address this question, seven leukaemia cell lines were
transfected with a temperature-sensitive p53 (tsp53)-encoding
vectororinfected with a wt-p53 recombinant retrovirus. Viral infec-
tion was used in addition to plasmid transfection to evaluate the
feasibility of a gene therapy approach based on wt-p53 expression
in leukaemia cells. Leukaemia cell lines corresponding to different
stages of the FAB classification (MI, M2, M3, M5 and M6) and
chronic myelogenous leukaemia in blast crisis (BC-CML) showing
morphological and cytochemical features of undifferentiated blast
cells (BV173) ormore differentiated erythroleukaemia cells (K562)
were used. We found that, after exogenous wt-p53 expression inde-
pendently of its origin (murine or human), only leukaemia cells
corresponding to Ml, M2 and M3 of the FAB classification or
showing features of undifferentiated blast cells undergo apoptosis.
Other leukaemia cells undergo maturation towards erythroid,
megakaryocytic or monocytic phenotypes. Interestingly, we also
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found thatcellresponsiveness top53 suppressoractivity isindepen-
dent ofthe status ofthe endogenousp53 gene.
MATERIALS AND METHODS
Cells, plasmids and recombinant viruses
HEL 92.1.7, U937, NB4, HL-60, KGI, BV173 and K562 cells
were cultured in RPMI-1640 medium supplemented with 10%
heat-inactivated fetal bovine serum (FBS). The Psi-2 crip-ampho
(Markowitz et al, 1988) amphotropic packaging cells were
cultured in Dulbecco's modified Eagle medium (DMEM) supple-
mented with 10% FBS. The plasmids pN53cG(Val-135), carrying
the ts-pS3Va-13S mutant gene (Soddu et al, 1994), and pRSVneo,
carrying the selectable marker for G418 resistance, were used. The
pLp53SN vector was obtained by inserting the human wt-p53
cDNA (Baker et al, 1990) into the unique BamHI site ofpLXSN
vectors (Miller and Rosman, 1989).
Transfections and infections
After 10 min incubation on ice, HEL 92.1.7, U937 and K562 cells
[5 x 106 in 0.3 ml ofphosphate-buffered saline (PBS)] were elec-
troporated (HEL 92.1.7: 0.25 kV, 960 [F; U937 and K562: 0.2 kV,
960 tF) with 10 gg ofplasmid, incubated for an additional 10 min
on ice and plated in complete medium. G418 was added after48 h
(HEL 92.1.7: 1 mg ml-'; U937 and K562: 750gg ml-'). HL-60
cells transfected with pN53cG(Val-135) (HL-2) and with
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pRSVneo (HL-60neo) have been described elsewhere (Soddu et
al, 1994). After 5 min at room temperature (RT), BV173 cells (1.4
X 107 cells in 0.5 ml ofmedium) were electroporated (0.3 kV, 960
,uF) with 20 jg of plasmid, incubated on ice for an additional 15
min and plated in complete medium. G418 (1 mg ml-) was added
after 48 h. After 10 min incubation on ice, NB4 cells [1.2 x 107 in
0.8 ml of transfection buffer (21 mM Hepes, pH 7.05, 137 mm
NaCl, 5 mM KCI, 0.7 mm Na2PO4 and 6 mM glucose)] were elec-
troporated (1.6 kV, 25 jiF) with 16 jg ofplasmid, incubated for an
additional 10min on ice, and plated in complete medium at a
concentration of0.5 x 106 cells ml-'. G418 (1 mg ml-') was added
after 48 h. Each electroporation was performed using a Gene-
Pulser (Bio-Rad Laboratories, Hercules, CA, USA). Stable trans-
fectants obtained by 3 weeks ofselection were maintained as mass
cultures or cloned by limiting dilution.
Virus-packaging cells were generated by stable transfection of
retroviral vectors in the Psi-2 crip ampho cell line. Selection
of stable transfectants was performed using 1.5 mg ml-' G418
for 2 weeks. Retroviral titration was performed as described
(Morgenstern and Land, 1990). To infect leukaemia cells, approx-
imately 5 x 105 packaging cells were treated for 2 h with 8 jg ml-1
mitomycin to inhibit cell replication. After 24 h from mitomycin
removal, 5 x 105 polybrene-treated leukaemia cells were co-
cultivated with the packaging cells. After 24 h of co-cultivation,
the infected cells were removed from the packaging layer and
plated in fresh medium. The LXSN- and pLp53SN-infected cells
were selected in G418-containing medium.
Immunoprecipitation and Western blotting
Approximately 1 x 106cells, unlabelled orlabelledwith 100jCiml-1
[35S]methionine were washed three times with cold PBS and incu-
bated for 15 min on ice in lysis buffer [50 mM Tris, pH 8, 150 mm
NaCl, 0.5% sodium deoxycholate, 0.1% sodium dodecyl sulphate
(SDS), 1% Nonidet P-40, 1 mm EDTA, 1 mM phenylmethyl-
sulphonyl fluoride, 16.5 jg ml-' aprotinin]. The lysates were
centrifuged at 1000OOg for 30min, and pellets were discarded.
Lysates containing equivalent amounts of proteins were incubated
for 90 min at 4°C with the anti-p53 antibodies [PAb421, PAb18O1
(Ab-l, Ab-2; Oncogene Science, Uniondale, NY, USA)]. Immuno-
complexes were washedfourtimes withlysisbuffer, boiledfor5 min
in sample buffer, analysed on a 10% SDS polyacrylamide gel and
subjected to fluorography or blotted onto nitrocellulose membranes.
After blocking non-specific reactivity with 2% non-fat dry milk
dissolved in TTBS (20 mm Tris-HCl, pH 7.8, 150 mm NaCl, 0.02%
Tween 20), membranes were incubated for 2 h at RT with a sheep
anti-p53 polyclonal antibody (Ab7; Oncogene Science), followed by
abiotinylated secondary antibody andperoxidase-conjugated avidin.
Immunoreactivity was detected by enhanced chemiluminescence
(ECL; Amersham, Bucks, UK), as instructed by the manufacturer.
Northern blot hybridization
Total cellular RNA was extracted by the guanidium thiocyanate
method (Chomczynski and Sacchi, 1987). A sample of 20,g of
RNA per lane was electrophoresed through 1.2% agarose gel in
the presence of formaldehyde. Gels were blotted and hybridized
using probes labelled with [32P]dCTP by random primerextension.
The cDNA of human p21 was kindly provided by B Volgelstein
(Johns Hopkins, Baltimore, PA, USA).
Proliferation and viability curves
Cells (1 x 105 ml-') were plated in 5 ml of fresh growth medium.
Cell numbers were determined in duplicate, at daily intervals, with
a Thoma's haemocytometer. Cell viability was determined by
trypan blue exclusion.
DNA sequencing
Total RNA was isolated as described above, and reverse transcrip-
tion was performed on 1- to 2-jig samples using Moloney murine
leukaemia virus reverse transcriptase (200 U; Pharmacia Biotech,
Milan, Italy). cDNA preparations and negative control template
were amplified by Taq polymerase (4 U) (AmpliTaq, Perkin-
Elmer, Milan, Italy) according to the manufacturer's instructions
using aPerkin-Elmer 9600 PCR machine programmed to carry out
38 cycles. Polymerase chain reaction (PCR) and DNA sequencing
primers were synthesized based on the cDNA sequence of p53
messenger RNA. PCR primers were prepared by Pharmacia
Biotech. Four sets of primers were used to cover the complete
protein coding region of the p53 cDNA (Sjogren et al, 1996).
Sequencing reactions were performed as described (Sjogren et al,
1996) with the use ofstreptavidin-coupled Sepharose HP attached
to the teeth ofplastic combs (solid-phase sequencing combs). The
comb was removed from sequencing reaction mixtures and
inserted into the wells ofthe ALF sequencing gel for 10 min. The
comb was then carefully removed from the gel apparatus, and
electrophoresis was initiated. The samples were analysed by
automated laser fluorescence (ALF express; Pharmacia Biotech)
sequencing gels. Evaluation ofp53 sequences was performed with
the aid ofthe DNAstar (DNAStar London) software program.
DNA fragmentation analysis
Cells (5 x 106) were collected by centrifugation, suspended in
400 jl of TET (10 mm Tris, pH 7.8, 1 mM EDTA, 0.2% Triton
Table 1 p53 status in leukaemia cell lines
Cell line p53 status Reference
HEL 92.1.7 Point mutation codons 72 and 132 By direct sequencing (this paper)
U937 Point mutation intron 5 Sugimoto et al (1992)
NB4 Point mutation codon 248 By direct sequencing (this paper)
HL60 Deletion Wolf et al (1985)
KG1 Point mutation intron 6 Sugimoto et al (1992)
BV173 Wild-type gene, overexpression Bi et al (1992)
K562 Wild-type gene, no expression Bi et al (1992)
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Figure 1 Endogenous and exogenous p53 protein expression in different leukaemia cells. Neo- and tsp53-transfected cells were maintained at 370C and
analysed for p53 protein expression. (A and B) Cells labelled with [35S]methionine were lysated and immunoprecipitated (see Materials and methods).
(C) Immune complexes obtained as in A and B were blotted and detected with sheep anti-p53 polyclonal antibody (Ab-7). Lanes 1, 2 and 3, neo polyclonal
populations; lanes 4, representative clone of tsp53-expressing cells; lanes 5, tsp53polyclonal populations. PAb421 (to murine and human p53 protein) in lanes
2, 4 and 5; PAb1801 (to human p53 only) in lanes 3; anti-mouse IgG (negative control) (in lanes 1). (D) Lysates containing 90 jig of total proteins and analysed
on sodium dodecyl sulphate-polyacrylamide gel electrophoresis (SDS-PAGE) as in A, B and C were blotted and detected with sheep anti-p53 polyclonal
antibody (Ab-7). Lanes 1 and 3, LXSN-infected cells; lanes 2 and 4, Lp53SN-infected cells
X-100) and processed for the selective isolation oflow-molecular-
weight DNA fragments as described previously (Duke et al, 1986).
DNA was analysed by electrophoresis on 1.5% agarose gel and
stained with 0.1,Ig mll ethidium bromide.
DNA content analysis
Cells harvested at the indicated times were fixed in cold
methanol-acetone (1:4) for 30 min at 4°C and stained in PBS
containing 50 ,ug ml-' propidium iodide (PI) and 2 mg ml-
RNAase A for 30 min at RT. DNA content was measured by an
Epics XL analyser (Coulter Corporation, Miami, FL, USA).
Indirect immunofluorescence
Cells were cytocentrifuged onto slides, fixed with absolute
methanol at -20°C for 30 min, rehydrated, preblocked for 30 min
at RT in PBS containing 3% FBS and incubated overnight at 4°C
with anti-p53 mAb 122 (Boehringer Mannheim Italia, Milan,
Italy). Immunoreaction was detected by incubation with an
affinity-purified, fluorescein isothiocyanate (FITC)-conjugated,
goat anti-mouse IgG (Cappel, West Chester, PA, USA).
Assessment of differentiation by analysis of cell
surface antigens
Cells (1 x 106) were incubated on ice for 1 h with 10 ,ul of
the following mAbs: anti-CD14, -CD1la, -CD1lb, -CDllc
(Labometrics, Milan, Italy), -CD45R (Sigma, St Louis, MO,
USA), -GpIIb/IIIa or -GpHIIa (Immunotech, Marseilles, France).
After immunoreaction, the cells were washed twice with PBS,
incubated for 45 min with FITC-conjugated anti-mouse IgG
(Cappel) and washed again with PBS. Fluorescence intensity was
measured by an Epics analyser (Coulter Corporation).
Assessment of erythroid differentiation
The phenotypical expression of erythroid differentiation was
monitored by the benzidine dihydrochloride test as described
previously (Rowley et al, 1981). Induction of haemoglobin
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synthesis was evaluated 4 days after the shift to 32°C in the pres-
ence or absence of 1 nM cytosine-p-D-arabino-furanoside (Ara-C;
Sigma) or 5 gM aphidicolin (Sigma). Benzidine positivity was
determined by scoring blue-stained cells under a light microscope.
At least 400 cells per sample were counted.
Assessment of cell differentiation by morphology,
a-naphthyl butyrate esterase and reduction of nitroblue
tetrazolium (NBT) analyses
Cytospin preparations (4 x 104 cells) were fixed and stained with
May-Grunwald-Giemsa. For a-naphthyl butyrate esterase
analysis, a kit (Sigma) was used as instructed by the manufacturer.
Positive red-brown-stained cells were scored under a light micro-
scope. To measure the capacity to phagocyte and reduce NBT,
5 x l05 cells in 1 ml ofgrowth medium were mixed with 100gl of
1% NBT solution (Sigma) and 100 ng ml-' phorbol 12-myristate
13-acetate (Sigma) and incubated at 37°C for 30 min. NBT posi-
tivity was determined by scoring 200 cells on Wright-stained cyto-
centrifuge preparations.
RESULTS
Endogenous p53 gene in leukaemia cell lines
Five acute myeloid leukaemia cell lines corresponding to different
stages ofFAB classification - KG1 acute myeloid leukaemia (Ml),
HL-60 myeloblastic leukaemia (M2), NB4 promyelocytic
leukaemia (M3), U937 monoblastoid leukaemia (M5) and HEL
92.1.7 erythroleukaemia (M6) - and two cell lines of BC-CML
showing diverse differentiation features - Ph-positive K562
erythroleukaemia and BV173 undifferentiated blast cells - were
used. The status ofthe endogenousp53 gene in five cell lines (see
Table 1) with the exclusion of the NB4 and HEL 92.1.7 has been
reported previously. By direct sequencing, the NB4pS3 gene was
shown to bear a single point mutation in the second nucleotide of
codon 248 (SF, unpublished). This mutation is a G-*A transition
resulting in the substitution of an arginine by a glutamine residue.
The mutation occurs in exon 7 in a highly conserved region. In the
HEL 92.1.7 cells, the status ofthe endogenous p53 protein was also
verified by direct sequencing (see Materials and methods). We
observed that, in HEL 92.1.7 cells, thep53 gene is mutated in the
second nucleotides of codons 72 (C--G transversion resulting in
the substitution ofaproline by an arginine residue) and 132 (T -*A
transversion resulting in the substitution ofamethionine by alysine
residue). These mutations occur in exons 4 and 5 respectively.
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Establishment of different leukaemia cell lines
expressing exogenous protein
The leukaemia cell lines were transfected with an expression
vector carrying the murine p53Vol 135 mutant gene. This mutant
encodes a temperature-sensitive protein that behaves like wt-p53
at 32°C, but not at 370C (Michalovitz et al, 1990). Cell clones
expressing the exogenous tsp53 gene were obtained from each cell
line except KG1, whereas cell clones expressing the neo marker
gene were obtained from all cell lines. To avoid the potential
pitfalls of studying the characteristics of selected clones, the
experiments were also performed using mixed populations that we
call BVtsp53, NB4tsp53, HL60tsp53, K562tsp53, U937tsp53 and
HELtsp53, expressing the tsp53 protein, and BV173, NB4, HL60,
K562, U937, HEL and KG1, expressing the selectable marker. The
expression oftsp53 protein in transfected cell lines was evaluated
by immunoprecipitation. Proteins from total cell lysates were
precipitated with two mAbs recognizing only endogenous human
p53 protein (PAbl8O1) orboth endogenous and exogenous murine
p53 protein (PAb421). Figure IA, B and C shows that similar
levels of exogenous tsp53 protein are expressed in clones and
mixed populations of different cell lines. Moreover, as expected
(see Table 1), endogenous p53 protein is uniquely detectable in
NB4, HEL 92.1.7 and BV173 cells. Typical expression of human
wt-p53 after viral infection is reported in Figure ID. HL-60 and
U937 cells devoid ofendogenous protein express similar levels to
the exogenous one. The expression levels of exogenous p53
protein in all cell lines, independently of the vector used for gene
transduction, are much greater than the physiological ones.
We assessed thebiological activity ofthe transfectedpS3 gene by
studying p21waflIciPl expression at the permissive temperature. The
increased levels of p21wafl/CciP mRNA in all tsp53-expressing cells
(Figure 2) demonstrate the functionality ofexogenous p53 protein.
Exogenous wt-p53 expression is not compatible with
the survival of KG1 cells
We never obtained stable transfectants of KGI cells in spite of
the repeated experiments and the different procedures used (e.g.
electroporation, CaPO4 precipitation, transferrin receptor-
mediated transfection or lipid-DNA complex methods). Similarly,
Lp53SN-infected KG1 cells died within 1 or 2 days from infec-
tion, during G418 selection. As KG1 cells infected with control
LXSN retrovirus survived to drug selection and proliferated as
well as parental KG1 cells (data not shown), we concluded that wt-
p53 was not compatible with the survival of KG1 cells.
co c1 c. o 0 o Co
GAPDH-i-
HEL BV173 U937 K562 NB4
Figure 2 Induction ofp2lwafl/pl mRNA by wt-p53 activity. Northern blot analysis of total cellular RNA derived from neo and tsp53 polyclonal populations.
Hybridization was performed with 32P-labelled human p21 and glyceraldehyde-3-phosphate dehydrogenase (GAPDH) probes
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Figure 3 Proliferation rate of tsp53-expressing cells. The cell numbers of cultures incubated at 370C or 320C were determined in duplicate. (U) Control and
(0) tsp53-expressing polyclonal populations incubated at 370C; (O) control and (0) tsp53-expressing polyclonal populations incubated at 320C
Exogenous wt-p53 induces apoptosis and growth
arrest in BV173 and NB4 cells
The tumour-suppressor activity of exogenous wt-p53 protein was
evaluated by studying cell proliferation, viability and differentia-
tion of transfected populations incubated at 32°C. The data
reported correspond to polyclonal populations, but similar data
were obtained using single cell clones (data not shown). The
proliferation rates of tsp53-expressing and control cells, reported
in Figure 3, show that exogenous wt-p53 completely inhibits
proliferation of BV173 and NB4 cells. To assess whether wt-p53
protein inhibits cell proliferation by promoting growth arrest
and/or inducing cell death, we evaluated cellular DNA content.
The histograms in Figure 4 indicate that, after 4 days at 32°C,
BVtsp53 cells (Figure 4A) accumulate in the GI phase of the cell
cycle and show a hypodiploid peak ofDNA corresponding to 40%
of total cell population, while NB4tsp53 cells exhibit a predomi-
nant hypodiploid peak (Figure 4B), which corresponds to approxi-
mately 90% of the total population. These results indicate that
exogenous wt-p53 expression reduces the proliferation rates of
NB4 and BV173 cells, inducing significant amounts ofcell death.
Accordingly, cell viability curves show a significant reduction
(40-50%) in viability, within 4 days, in BVtsp53 cells and causes
all NB4tsp53 cells to die within 2 days (Figure 5). Moreover, DNA
fragmentation analysis ofBVtsp53 and NB4tsp53 cells maintained
at 32°C for 4 and 2 days, respectively, showed a DNA ladder in
both cell populations (Figure 6A and B). The effects of exogenous
wt-p53 in NB4 and BV173 cells were also verified using retroviral
vectors. We observed that Lp53SN-infected NB4 and BV173 cells
died during G418 selection. As LXSN-infected cells survive to
drug selection and proliferate as parental cells (data not shown),
we conclude that the expression of exogenous wt-p53 is not
compatible with the survival ofNB4 and BV173 cells.
Considering that cell death is often concomitant with differenti-
ation, we evaluated whether exogenous wt-p53 expression also
induced these cells to differentiate. Different assays were used
depending on the histotype ofthe transfected leukaemia cells. NB4
are promyelocytic leukaemia cells with a PML/RARa transloca-
tion that are known to undergo granulocytic differentiation upon
retinoic acid treatment (Lanotte et al, 1991), whereas BV173 cells
are a BC-CML with morphological and cytochemical features of
undifferentiated lymphoid blast cells. BV173 cells are considered
to be a clonal expansion of leukaemia cells blocked at an earlier
differentiation stage, in comparison with the other Ph-positive
K562 cell line used in this work (Pegoraro et al, 1983). NB4 and
BVI73 cell differentiation was studied analysing granulocytic
and lymphocytic markers respectively. The percentages of cells
displaying CD14, CD1lb, CD1lc or CD45 cell-surface antigens
were evaluated, together with the morphological features and the
ability to phagocyte and reduce NBT. The data reported in Table 2
indicate that exogenous wt-p53 does not promote differentiation in
either BV173 or NB4 cells.
Exogenous wt-p53 induces apoptosis and
differentiation in HL-60 cells
We have reported previously (Soddu et al, 1994) that HL-60 cells
undergo spontaneous differentiation not preceded by G1 arrest
upon exogenous wt-p53 expression. We have also reported that
tsp53-expressing HL-60 cells show a 15-20% reduction in cell
viability during differentiation, which is accompanied by morpho-
logical and biochemical signs ofapoptosis (Soddu et al, 1994). By
using retroviral infection, we confirmed that HL-60 cells, infected
with the Lp53SN retrovirus and selected in G418, showed reduced
proliferation and survival capacity. Indeed, DNA content analysis
ofinfected HL-60 cells, after G418 selection (3 weeks after infec-
tion), showed that the hypodiploid peak corresponding to dead
cells was significantly higher in Lp53SN-infected cells (35% of
total population) than in LXSN control-infected cells (10%)
(Figure 7A). Indirect immunofluorescence confirmed that exoge-
nous p53 protein was expressed in these cells (Figure 7B), thus
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Figure 5 Cell viability of NB4 and BV173 cells expressing tsp53 protein.
Cell viability was determined by trypan blue exclusion. (U) control and
(0) tsp53-expressing cells incubated at 37°C; (El) control and (0) tsp53-
expressing cells incubated at 320C. Data are from polyclonal populations
Figure 4 DNA content analysis of NB4, BV1 73 and K562 cells expressing
tsp53 protein. Cells cultured at 320C and 370C for 2 days (NB4) or 4 days
(BV173 and K562) were fixed, stained with PI and analysed by flow
cytometry. (A) Control and tsp53-expressing NB4 cells; (B) control and tsp53-
expressing BV173 cells; (C) control and tsp53-expressing K562 cells. Data
are from polyclonal populations
indicating that increased cell death should be attributed to
constitutive expression of wt-p53 protein. Different expression
levels of exogenous p53 might be responsible for the observation
that only a fraction of positive cells undergo apoptosis. This
hypothesis is in good agreement with data reported previously
using vaccinia vectors (Ronen et al, 1996). The fact that other
haemopoietic cells infected with this retrovirus respond to wt-p53-
suppressing activity 3 weeks after infection has been reported
previously (Martinelli et al, 1997) but cannot easily be explained.
It can be speculated that, during the selection procedure, differen-
tiation and apoptosis occurs concomitantly and that the relative
amounts depend upon the expression levels of wt-p53 protein
(Ronen et al, 1996). Interestingly, after several passages, infected
HL-60 lost wt-p53 activity, suggesting that, in these cells, there are
still active molecular mechanism(s), which select against wt-p53
expression.
Exogenous wt-p53 induces differentiation in K562 and
HEL 92.1.7, but it has no effect on U937 cells
Figure 3 shows that exogenous wt-p53 promotes a mild reduction
in K562tsp53 cell proliferation with respect to the neo controls
(K562), while it does not affect U937 and HEL 92.1.7 cells. DNA
content analysis oftsp53-expressing K562 cells (Figure 4 C) after4
days at 32°C shows neitherchanges in the distribution ofthe cells in
the different phases of the cell cycle nor a subdiploid peak. As the
patterns of DNA content do not change after different incubation
times at the permissive temperature, it is inferred that the mild
reduction in the proliferation rate observed in K526tsp53 cells
(Figure 3) is caused by alterations in kinetics parameters, which
modify all phases ofthe cell cycle to the same extent. Fluorimetric
analyses of DNA content (data not shown) indicate that U937 and
HEL 92.1.7 leukaemic cells expressing exogenous wt-p53 survive
as well as neo control cells, in agreement with the proliferation
curves reported in Figure 3. Data reported in Figures 3 and 4 corre-
spond to polyclonal populations, but similar data were obtained
using single cell clones (data not shown). Similar results were
obtained after retroviral infection of K562, U937 and HEL 92.1.7.
These cells, infected with the Lp53SN retrovirus and selected in
G418, survived and proliferated to the same extent as control
LXSN-infected cells, thus confirming that wt-p53 expression does
not influence their growth. Interestingly, as observed for HL-60
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Figure 6 DNA fragmentation analysis of BV173 and NB4 cells expressing
tsp53 protein. (A) BV173 and BVtsp53 cells; (B) NB4 and NB4tsp53 cells.
BVtsp53 and NB4tsp53 cells were shifted at 320C for 4 or 2 days,
respectively, before DNA fragmentation analysis. DNA fragments were
separated onto 1.5% agarose gel and stained with ethidium bromide
cells, infected K562 cells lostwt-p53 activity afterseveral passages,
suggesting that, in these cells also, there are still active molecular
mechanism(s), which select against wt-p53 (data not shown).
K562 cells are considered a clonal expansion ofleukaemia cells
blocked at later differentiation stage with respect to BV173 cells
(Pegoraro et al, 1983). Using the benzidine test, we evaluated
differentiation-associated haemoglobin synthesis in K562tsp53
cells shifted to 32°C. Spontaneous erythroid differentiation was
detected in approximately 15% ofthe cells (Table 2), in agreement
with data reported previously (Feinstein et al, 1992). Thus, wt-p53
protein per se promotes differentiation in K562 cells. It has been
reported (Rowley et al, 1981) that K562 cells could be induced to
synthesize haemoglobin by treatment with various agents (e.g.
Ara-C, aphidicolin and butyric acid). To assess whether wt-p53
facilitates the differentiation process in the presence ofdifferentia-
tion inducers, K562tsp53 cells were incubated at 32°C in the pres-
ence of 1 nm Ara-C or 5 gM aphidicolin. Figure 8 shows a twofold
increase in the numberofhaemoglobin-expressing cells,compared
with untreated tsp53 transfectants or treated control cells. These
results indicate that, in these leukaemia cells, wt-p53 protein may
act in concert with other differentiation inducers.
HEL 92.1.7 is a bipotent cell line. These cells express antigens
of erythroid and megakaryocytic phenotypes that increase after
treatment with haemin or phorbol myristate acetate (PMA) (Long
et al, 1991). Thus, we evaluated the percentage of haemoglobin-
positive andGpIIb/IIIa- orGpIIIa-positive cells to check erythroid
and megakaryocytic differentiation respectively. Thehaemoglobin
content was measured by benzidine staining after 4 days of incu-
bation at 32°C in the presence or absence of50 mM haemin. These
analyses showed that wt-p53 expression, by itselfor in association
with haemin, does not increase haemoglobin expression in HEL
92.1.7 cells. The cells were also incubated with mAbs to the
GpIIb/IIIa or GpIIIa glycoproteins and analysed by flow cyto-
metry to assess megakaryocytic differentiation. No quantitative
changes in GpHb/IIIa expression were observed up to 4 days after
the shift to 32°C. However, at that time, the number of cells
expressing the GpIIIa antigen was significantly increased (69% vs
Table 2 Wt-p53 effects on cell differentiation
Cell Assays Parental tsp53-transfected
lines cells cells
HEL 92.1.7 Benzidine + (%) < 1.0 < 1.0
cytofluormetry: Gpilb/lila 13.1% 15.2%
Gpilla 16.2% 66.9%
U937 Esterase 62.2% 63%
Cytofluorimetry: CD14 24% 16.6%
CD11c 4.9% 6.7%
NBT+ (%) < 1.0 < 1.0
NB4 May-Grunwald-Giemsa No phenotypic changes No phenotypic changes
Cytofluonmetry: CD14 Negative Negative
CD11b 14% 5.4%
CD11c 14.9% 11.4%
NBT+ (%) < 1.0 < 1.0
HL60a May-Grunwald-Giemsa 10% myelocytes 45% mielocytes/neutrophils
Cytofluorimetry: CD14 < 10% < 10%
CD15 20% 70%
NBT + (%) 13 33
BV173 Cytofluorimetry: CD45R 5.7% 5.8%
K562 Benzidine + (%) 0.1 15
Wt-p53 effects were evaluated 4 days after the shift to the permissive temperature. Values correspond to polyclonal populations, but similar
data are obtained using single cell clones. aSee Soddu et al (1994).
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Figure 7 DNA content analysis and wt-p53 expression of HL60 cells after
retroviral infection. DNA content analysis (A) and wt-p53 expression (B) of
HL-60 cells infected with Lp53SN or LXSN (control) retroviruses. In different
experiments, 75-85% of the cells were positive to anti-p53 Ab122 with
nuclear staining. The arrow indicates a cell in metaphase
16%) (Table 2). These results indicate that HEL 92.1.7 cells
respond to exogenous wt-p53 expression by partially maturing
through the megakaryocytic pathway.
Monoblastoid U937 leukaemia cells can be induced to differen-
tiate along the monocyte/macrophage lineage by a variety of
agents (Olsson and Breitman, 1982). The differentiation process is
accompanied by several morphological and functional changes.
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Figure 8 Differentiation of K562 cells expressing tsp53 protein in the
presence or absence of differentiation inducers. Polyclonal populations of
parental and tsp53-expressing K562 cells were cultured in the presence or
absence of 5 gM aphidicolin or 1 nm Ara-C at 320C. Benzidine-positive cells
were evaluated after 7 days of culture at 320C. Values are means of three
separate experiments ± s.d
These include the expression of a-naphthyl-butirate esterase and
the ability to phagocyte and reduce NBT. We found that tsp53-
expressing and control U937 cells display indistinguishable
behaviours (Table 2). Moreover, U937 cells infected with the
Lp53SN retrovirus and selected in G418 also showed inability to
differentiate to the same extent as control LXSN-infected cells.
These findings are in contrast with aprevious report (Ehinger et al,
1996), indicating that wt-p53 protein promotes U937 differentia-
tion. We supposed that such conflicting results might be explained
by different degrees of differentiation of diverse U937 cell lines.
The expression of the CD15, CD14 and CDllc antigens in our
cells was similar to that reported previously (Ehinger et al, 1996),
but we cannot exclude that other differences acquired during
prolonged in vitro passages might be responsible for different
results. This hypothesis is supported, at least in part, by the
evidence that our U937 parental cells, after treatment with vitamin
D3, differentiate only with the concomitant presence of TGFj3
(GB and SS, unpublished observations), whereas the wt-p53-
responsive U937 cells differentiate after exposure to vitamin D3
alone (Ehinger et al, 1996). This observation suggests that
different U937 populations are notequally prone to differentiation,
further supporting the notion that the cellular context is relevant in
determining the outcome ofwt-p53 action.
DISCUSSION
In this paper, we report that wt-p53 induces (1) apoptosis and
growth arrest in KG1 (MI), NB4 (M3) and BV173 (BC-CML)
cells lines; (2) apoptosis and differentiation in HL-60 (M2) cell
line; and (3) differentiation or no effect in K562 (BC-CML) and
HEL 92.1.7 (M6) or U937 (M5) cell lines respectively. To our
knowledge, this is the first report that compares the susceptibility to
exogenous wt-p53 protein ofleukaemia cell lines corresponding to
different stages of differentiation. Leukaemia cells that undergo
apoptosis in response to exogenous wt-p53 expression appear to be
ideal targets for a gene therapy approach to bone marrow purging
with the wt-p53 gene. Thus, an important question preliminary
to p53 gene replacement attempts is to define which leukaemia
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subgroups are susceptible to such therapy. Interestingly, we found
that specific differentiation phenotypes ofleukaemia cells appear to
correlate with the outcome (apoptosis) ofthe cells after exogenous
wt-p53 expression. Exogenous wt-p53 protein expression generates
apoptosis only in leukaemia cell lines corresponding to Ml, M2
and M3 of the FAB classification and in BC-CML showing
undifferentiated blast phenotype (KG1, NB4, HL-60 and BV173
respectively), but promotes further maturation in the others.
The existing literature suggests that the status of endogenous
p53 should be a major determinant ofresponsiveness. The absence
ofp53 would have been predicted to provide maximal responsive-
ness, and the presence of a dominant-negative mutant should
interfere with the action of any exogenous wt-p53. In contrast,
leukaemia bearing a wt-p53 would not have been predicted to be a
suitable target for p53 gene therapy. Unexpectedly, our results
show that the status of the endogenous p53 is a poor predictor of
the final outcome. First, the absence of the endogenous protein
does not generate identical effects in U937, HL-60 and K562 cells,
being unresponsive in U937 cells while HL-60 and K562 cells are
induced to apoptosis and/or differentiation. Secondly, the presence
of an endogenous, mutant p53 protein is not a major factor in
determining whether a cell would undergo apoptosis or survive in
response to exogenous wt-p53 expression, as observed in KGl,
NB4 and HEL 92.1.7 cells. Thirdly, the presence ofan endogenous
wt-p53 protein does not prevent apoptosis, as observed in BV173
cells. Furthermore, the final fates observed in leukaemia cells
cannot simply be attributed to variations in the levels of wt-p53
protein expression. The fate of each cell type was the same
whether different clones or polyclonal populations were analysed
and was independent of the vector used. However, as it might be
postulated that diverse cell lines may tolerate different threshold
levels of p53 before exhibiting final biological effects, we cannot
exclude that different levels of exogenous wt-p53 expression can
also contribute to determining the final outcome.
The dependence of wt-p53 action on the cellular environment
generated by differentiation parallels previous reports (Canman
et al, 1995; Soddu et al, 1996). However, there are no simple
explanations for the observation that apparently only cells corre-
sponding to specific stages of differentiation are susceptible to
apoptosis upon exogenous wt-p53 expression. An explanation for
these results might be that apoptosis does not occur in cells
committed for terminal differentiation, because they have lost the
ability to undergo apoptosis. This hypothesis is in good agreement
with the finding that wt-p53 expression is induced at early stages
in the differentiation process (Kastan et al, 1991). The well-
accepted notion that wt-p53 is normally inactive in differentiated
cells unless it is required by stressing conditions (e.g. DNA
damage) further supports this view. Moreover, it has been reported
that differentiated haematopoietic cells are less prone to apoptotic
death than their undifferentiated precursors (Williams et al, 1990).
In this scenario, it might be speculated that forced expression of
wt-p53 normalizes the cellular functions of leukaemia cells and
allows them to respond to intracellular signals, which drive the cell
to apoptosis or differentiation.
In conclusion, our results indicate that (1) leukaemia cells
showing a monocytic, erythroid or megakaryocytic differentiated
phenotype are less relevant for p53 gene therapy; (2) retroviral
infection can be used to generate a therapeutically useful outcome
(apoptosis) in leukaemia cells corresponding to Ml, M2 and M3 of
the FAB classification or in BC-CML blocked at an early stage of
differentiation; (3) the status ofendogenous p53 protein does not by
itself determine the final effects induced by exogenous wt-p53
expression. Thus, restoration of the p53 tumour-suppressor gene
expression holds promises in the quest for a genetically based
suppression of the tumorigenic phenotype, at least in the human
leukaemia showing morphological and cytochemical features of
myelocytic differentiation or undifferentiated blasts. Further studies
have to be performed on primary cells from leukaemia patients to
confirm thatwt-p53-suppressive action occurs whenleukaemiacells
are blocked by transformation at specific stages ofdifferentiation.
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